The Randomized Aldactone Evaluation Study (RALES) [8], the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) [9] and Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) [10] clinical trials have demonstrated that the addition of MR antagonists to standard care markedly reduced the overall and cardiovascular mortality in patients with left ventricular systolic dysfunction and mild or severe symptoms of chronic heart failure (HF) or with signs of HF after acute myocardial infarction. Here, NR3C2 is linked to acute myocardial infarction.